In this touchIMMUNOLOGY interview, we speak with Dr. Jayne Doherty (St Vincent’s University Hospital, Dublin, Ireland) around her study, which investigated the impact of inflammatory bowel disease (IBD) and of TNF inhibitor therapy for treatment of IBD on antibody responses to vaccination against COVID-19.
The abstract entitled ‘REDUCED SEROLOGICAL RESPONSE TO COVID-19 BOOSTER VACCINES IN PATIENTS WITH IBD IS FURTHER DIMINISHED BY TNF INHIBITOR THERAPY; VARIATION STUDY PART 2 (VARIABILITY IN RESPONSE IN IBD AGAINST SARS-COV-2 IMMUNISATION)’ (Abstract no: OP137) was presented at UEG Week, October 8 – 11, 2022.
Questions
- What is known about the response to COVID-19 vaccinations in patients with inflammatory bowel disease (IBD)? (0:34)
- What were the eligibility criteria of your study? (2:29)
- What were the vaccine responses in patients with IBD and in those taking TNF antagonists? (3:15)
- On the basis of these findings, what are your recommendations for patients with IBD who are taking TNF antagonists?
Disclosures: Jayne Doherty has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed as a highlight of UEG Week 2022.
